The results showed that in addition to the previously mentioned primary therapy outcome (PD & SD & PR vs. CR, HR = 4.528, 95% CI: 2.885–7.107, p < 0.001) and age (>65 vs. ≤65, HR = 1.744, 95% CI: 1.121–2.712, p = 0.014), high GGT5 expression was also an independent prognostic factor for worse overall survival in gastric cancer patients (HR = 1.724, 95% CI: 1.094–2.717, p = 0.019) (Table 3 and Figure 4B). The gene discussed is GGT5; the disease is gastric cancer.